Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Virol ; 78(6): 2841-52, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14990703

ABSTRACT

Individuals infected with human immunodeficiency virus type 1 (HIV-1) subtype C infrequently harbour X4 viruses. We studied R5 and X4 biological clones generated from HIV-1 subtype C-infected individuals. All subtype C R5 viruses demonstrated slower profiles of replication on CD4(+) lymphocytes in comparison to subtype B viruses, whereas subtype C X4 viruses replicated with comparable efficiency to subtype B X4 viruses. No differences were identified in CC or CXC chemokine inhibitions (RANTES and SDF-1alpha, respectively) between subtype C and subtype B viruses. Immature dendritic cells were shown in coculture experiments to similarly enhance the infection of subtype C and subtype B R5 as well as X4 viruses. By amino acid sequence analysis, we showed that the R5 and X4 subtype C gp120 envelope gene alterations were similar to those for a switching subtype B virus, specifically with respect to the V3 charge and envelope N-linked glycosylation patterns. By phylogenetic analysis, we showed that one patient was infected with HIV-1 C' and the other was infected with HIV-1 C" and that one of the patients harbored a virus that was a recombinant in the gp120 env gene between an R5 and an X4 virus, with the resultant virus being R5. No differences were identified between the long terminal repeat regions of the subtype C R5 and X4 biological clones. These results indicate that even though R5 subtype C viruses are restrictive for virus replication, the R5-to-X4 phenotype switch can occur and does so in a manner similar to that of subtype B viruses.


Subject(s)
HIV Infections/virology , HIV-1/classification , HIV-1/metabolism , Receptors, CCR5/metabolism , Receptors, CXCR4/metabolism , Amino Acid Sequence , Cells, Cultured , Genotype , HIV Envelope Protein gp120/genetics , HIV-1/genetics , HIV-1/pathogenicity , Humans , Molecular Sequence Data , Phenotype , Phylogeny , Sequence Analysis, DNA , Virus Replication
2.
J Virol ; 78(1): 524-30, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14671134

ABSTRACT

We studied human immunodeficiency virus type 1 (HIV-1) chimeric viruses altering in their gp120 V1V2 and V3 envelope regions to better map which genetic alterations are associated with specific virus phenotypes associated with HIV-1 disease progression. The V1V2 and V3 regions studied were based on viruses isolated from an individual with progressing HIV-1 disease. Higher V3 charges were linked with CXCR4 usage, but only when considered within a specific V1V2 and V3 N-linked glycosylation context. When the virus gained R5X4 dual tropism, irrespective of its V3 charge, it became highly resistant to inhibition by RANTES and highly sensitive to inhibition by SDF-1alpha. R5 viruses with higher positive V3 charges were more sensitive to inhibition by RANTES, while R5X4 dualtropic viruses with higher positive V3 charges were more resistant to inhibition by SDF-1alpha. Loss of the V3 N-linked glycosylation event rendered the virus more resistant to inhibition by SDF-1alpha. The same alterations in the V1V2 and V3 regions influenced the extent to which the viruses were neutralized with soluble CD4, as well as monoclonal antibodies b12 and 2G12, but not monoclonal antibody 2F5. These results further identify a complex set of alterations within the V1V2 and V3 regions of HIV-1 that can be selected in the host via alterations of coreceptor usage, CC/CXC chemokine inhibition, CD4 binding, and antibody neutralization.


Subject(s)
HIV Envelope Protein gp120/genetics , HIV Infections/immunology , HIV Infections/physiopathology , HIV-1/pathogenicity , Peptide Fragments/genetics , Receptors, CCR5/metabolism , Receptors, CXCR4/metabolism , Antibodies, Monoclonal/pharmacology , CD4 Antigens/metabolism , Chemokine CCL5/pharmacology , Chemokine CXCL12 , Chemokines, CC/pharmacology , Chemokines, CXC/pharmacology , Disease Progression , HIV Envelope Protein gp120/chemistry , HIV Infections/virology , HIV-1/drug effects , HIV-1/immunology , Humans , Mutation , Neutralization Tests , Solubility
SELECTION OF CITATIONS
SEARCH DETAIL
...